Targeting Akt by SC66 triggers GSK-3β mediated apoptosis in colon cancer therapy

BACKGROUND: Colon cancer is one of the three common malignant tumors, with lower 5 years survival rate. Akt is an important therapeutic target, while SC66 is a novel allosteric AKT inhibitor, which enhances the therapeutic effect in several types of cancer. However, the molecular mechanisms of targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yeying, Huang, Yuan, Ding, Jie, Liu, Nannan, Peng, Shuang, Wang, Jiangang, Wang, Feng, Zhang, Yingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509835/
https://www.ncbi.nlm.nih.gov/pubmed/31168297
http://dx.doi.org/10.1186/s12935-019-0837-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509835/
https://www.ncbi.nlm.nih.gov/pubmed/31168297
http://dx.doi.org/10.1186/s12935-019-0837-7

Ejemplares similares